JP2022537134A5 - - Google Patents

Info

Publication number
JP2022537134A5
JP2022537134A5 JP2021573297A JP2021573297A JP2022537134A5 JP 2022537134 A5 JP2022537134 A5 JP 2022537134A5 JP 2021573297 A JP2021573297 A JP 2021573297A JP 2021573297 A JP2021573297 A JP 2021573297A JP 2022537134 A5 JP2022537134 A5 JP 2022537134A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
days
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537134A (ja
JP7705353B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000443 external-priority patent/WO2020250033A1/en
Publication of JP2022537134A publication Critical patent/JP2022537134A/ja
Publication of JP2022537134A5 publication Critical patent/JP2022537134A5/ja
Application granted granted Critical
Publication of JP7705353B2 publication Critical patent/JP7705353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573297A 2019-06-10 2020-06-09 Cd38抗体を使用する併用療法 Active JP7705353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859631P 2019-06-10 2019-06-10
US62/859,631 2019-06-10
PCT/IB2020/000443 WO2020250033A1 (en) 2019-06-10 2020-06-09 Combination therapies using cd-38 antibodies

Publications (3)

Publication Number Publication Date
JP2022537134A JP2022537134A (ja) 2022-08-24
JP2022537134A5 true JP2022537134A5 (cg-RX-API-DMAC7.html) 2023-06-20
JP7705353B2 JP7705353B2 (ja) 2025-07-09

Family

ID=71527822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573297A Active JP7705353B2 (ja) 2019-06-10 2020-06-09 Cd38抗体を使用する併用療法

Country Status (7)

Country Link
US (1) US20220241413A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980064A1 (cg-RX-API-DMAC7.html)
JP (1) JP7705353B2 (cg-RX-API-DMAC7.html)
CN (1) CN113993543B (cg-RX-API-DMAC7.html)
AR (1) AR120054A1 (cg-RX-API-DMAC7.html)
TW (1) TWI870415B (cg-RX-API-DMAC7.html)
WO (1) WO2020250033A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024392986A1 (en) * 2023-12-06 2026-07-16 Sanofi-Aventis U.S. Llc Use of anti-cd38 antibody in the treatment of new diagnosed multiple myeloma

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
IT1320715B1 (it) 2000-10-19 2003-12-10 Cselt Centro Studi Lab Telecom Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
KR20110028450A (ko) 2008-06-16 2011-03-18 이뮤노젠 아이엔씨 새로운 상승 효과
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
US8877899B2 (en) 2010-09-27 2014-11-04 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
CN105228700A (zh) * 2013-03-13 2016-01-06 炎症反应研究公司 左西替利嗪和孟鲁司特在治疗自身免疫病中的用途
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
MA41555A (fr) 2015-02-17 2017-12-26 Millennium Pharm Inc Polythérapie pour le traitement du cancer
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
JP7027321B2 (ja) * 2015-11-03 2022-03-01 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体の皮下製剤及びその使用
US20170121417A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
MA45674A (fr) * 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
US20180117150A1 (en) * 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
EP3544612A4 (en) * 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. PHARMACEUTICAL COMBINATIONS COMPRISING A HISTONE DEACETYLASE INHIBITOR AND A CD38 INHIBITOR AND METHODS OF USING THE SAME
US11618787B2 (en) * 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
US20200308296A1 (en) * 2019-03-28 2020-10-01 Janssen Biotech, Inc. Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone
CN120501855A (zh) * 2019-05-14 2025-08-19 赛诺菲-安万特美国有限责任公司 给予抗cd38抗体以治疗多发性骨髓瘤的方法

Similar Documents

Publication Publication Date Title
JP2021525248A5 (cg-RX-API-DMAC7.html)
US11591406B2 (en) Treatment for multiple myeloma (MM)
JP2023524149A5 (cg-RX-API-DMAC7.html)
JP2021528423A5 (cg-RX-API-DMAC7.html)
JP2023544407A5 (cg-RX-API-DMAC7.html)
JP2023542289A5 (cg-RX-API-DMAC7.html)
JP2021513540A5 (cg-RX-API-DMAC7.html)
JP2013539352A5 (cg-RX-API-DMAC7.html)
JP2009533367A5 (cg-RX-API-DMAC7.html)
JP2023540795A5 (cg-RX-API-DMAC7.html)
JP2024534602A5 (cg-RX-API-DMAC7.html)
JP2023520771A5 (cg-RX-API-DMAC7.html)
JP2022532356A5 (cg-RX-API-DMAC7.html)
JP2022512851A5 (cg-RX-API-DMAC7.html)
JP2022523372A5 (cg-RX-API-DMAC7.html)
JP2020515577A5 (cg-RX-API-DMAC7.html)
JP2024069230A5 (cg-RX-API-DMAC7.html)
JP2018529661A5 (cg-RX-API-DMAC7.html)
WO2018072743A1 (zh) Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
JP2022542472A5 (cg-RX-API-DMAC7.html)
JP2022513029A5 (cg-RX-API-DMAC7.html)
CN114450025A (zh) 使用包含多重酪氨酸激酶抑制剂和免疫检查点抑制剂的组合治疗癌症
JP2023546504A5 (cg-RX-API-DMAC7.html)
JP2022521773A5 (cg-RX-API-DMAC7.html)
TW202034925A (zh) Cdk4/6抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途